1,189
Views
110
CrossRef citations to date
0
Altmetric
Review

Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus

Pages 169-183 | Published online: 23 May 2014

Abstract

Type 2 diabetes mellitus (T2DM) is commonly accompanied by other cardiovascular disease (CVD) risk factors, such as hypertension, obesity, and dyslipidemia. Furthermore, CVD is the most common cause of death in people with T2DM. It is therefore of critical importance to minimize the risk of macrovascular complications by carefully managing modifiable CVD risk factors in patients with T2DM. Therapeutic strategies should include lifestyle and pharmacological interventions targeting hyperglycemia, hypertension, dyslipidemia, obesity, cigarette smoking, physical inactivity, and prothrombotic factors. This article discusses the impact of modifying these CVD risk factors in the context of T2DM; the clinical evidence is summarized, and current guidelines are also discussed. The cardiovascular benefits of smoking cessation, increasing physical activity, and reducing low-density lipoprotein cholesterol and blood pressure are well established. For aspirin therapy, any cardiovascular benefits must be balanced against the associated bleeding risk, with current evidence supporting this strategy only in certain patients who are at increased CVD risk. Although overweight, obesity, and hyperglycemia are clearly associated with increased cardiovascular risk, the effect of their modification on this risk is less well defined by available clinical trial evidence. However, for glucose-lowering drugs, further evidence is expected from several ongoing cardiovascular outcome trials. Taken together, the evidence highlights the value of early intervention and targeting multiple risk factors with both lifestyle and pharmacological strategies to give the best chance of reducing macrovascular complications in the long term.

Introduction

A seemingly relentless increase in the incidence of diabetesCitation1 finds us in the midst of a global diabetes epidemic. More than 382 million people are currently affected worldwide, and this number is expected to rise to 592 million by 2035.Citation2 The latest statistics for the US indicate that over 25 million people, or 8.3% of the population, are affected,Citation3 and another 79 million with prediabetes are at increased risk of developing the disease. The dynamics of the diabetes epidemic are also changing rapidly. Once a disease of the West and the affluent, type 2 diabetes mellitus (T2DM) has now spread to every country in the world and is increasingly common among the less wealthy. Notably, Asia’s large population and rapid economic development have made it an epicenter of the epidemic. Furthermore, rising rates of childhood obesity have resulted in T2DM becoming more common in children and adolescents, particularly in certain ethnic groups.Citation2

Diabetes is a major risk factor for cardiovascular disease (CVD), and CVD is the most common cause of death in people with diabetes. Various studies have indicated that, relative to those without diabetes, the presence of diabetes significantly increases the risk (two- to fourfold) for developing CVD,Citation4Citation9 and of dying when CVD is present.Citation9Citation13 In the US in 2004, heart disease was noted on 68% of diabetes-related death certificates among people aged 65 years or older, and stroke was noted on 16%.Citation3 Although rates of death attributable to CVD have declined in people with and without diabetes,Citation14 the burden of CVD in those with diabetes remains high, and implementation of preventive strategies is frequently not adequate.Citation15Citation17 Individuals with prediabetes also have an increased risk of CVD. Indeed, it has been suggested that CVD risk reduction and prevention of diabetes in the prediabetes population may do more to reduce the CVD burden than aggressive treatment of CVD risk factors once diabetes has fully developed.Citation18

T2DM is associated with clustered risk factors for CVD. Adults with diabetes have a 77%–87% prevalence of hypertension, a 74%–81% prevalence of elevated low-density lipoprotein cholesterol (LDL-C), and a 62%–67% prevalence of obesity.Citation19 The increased risk of CVD in patients with diabetes is related in part to this high prevalence of other CVD risk factors. The management of modifiable CVD risk factors, including hyperglycemia, hypertension, dyslipidemia, obesity, cigarette smoking, and physical inactivity, is therefore critical to minimizing the risk of macrovascular complications of diabetes.

Although critically important, these traditional risk factors do not fully explain the excess risk for CVD in people with diabetes, and there have also been efforts to identify and understand the link between diabetes and other “nontraditional” CVD risk factors, such as endothelial dysfunction, impaired fibrinolysis, inflammation, microalbuminuria, increased homocysteine levels, and vascular wall abnormalities. An assessment of the clinical utility of such nontraditional risk factors by the US Preventive Services Task Force concluded that there was insufficient evidence to recommend using them to assess CVD risk in the general population.Citation20,Citation21 Although there is some evidence regarding their role in diabetes,Citation22Citation24 it has not been conclusively determined whether it is of clinical benefit to screen for or therapeutically target these nontraditional risk factors, and their management has not been incorporated into diabetes guidelines. This article will therefore focus on how the modification of traditional risk factors impacts CVD risk in patients with T2DM, and discuss current guidelines in this regard.

Lifestyle interventions

Lifestyle management is universally advocated for prevention as well as management of T2DM. Lifestyle interventions generally include healthy eating, increased physical activity, and cessation of smoking. Such interventions have several beneficial effects, and can also have an impact on CVD risk.

Weight loss

Weight loss is advised for all overweight or obese patients with T2DM. Recommended strategies to reduce weight include regular physical activity and maintaining a healthy eating pattern.Citation25Citation27 An association between overweight/obesity and an increased risk of CVD is well established in the general population.Citation28 Furthermore, studies have shown that overweight and obesity, particularly visceral obesity, increase the risk of developing T2DM.Citation29,Citation30 The presence of inflammation leading to insulin resistance has been proposed as the mechanistic link between obesity and diabetes.Citation31,Citation32 In the context of T2DM, the relationship between weight change and CVD risk is complicated by the issue of how to adjust for such confounding factors as hypertension, dyslipidemia, and hyperglycemia, and conflicting results have made it difficult to conclusively state that weight loss is linked with a reduction in CVD risk. Nevertheless, other benefits of weight loss have been clearly demonstrated (eg, improvements in quality of life, insulin resistance, and other CVD risk factors), and clinical guidelines therefore continue to recommend weight loss for overweight or obese individuals with T2DM.

Look AHEAD (Action for Health in Diabetes; see for full trial names) tested the hypothesis that weight loss in patients with T2DM could reduce the risk of CV events.Citation33 Participants were randomized to an intensive lifestyle-modification program of caloric restriction combined with 175 minutes per week of moderate-intensity physical activity, or to a standard program of diabetes education. Although intensive lifestyle intervention was associated with significant weight loss and improvements in several CVD risk factors, there was no effect on the rate of CV events during long-term follow-up, and the trial was stopped for reasons of futility after a median follow-up of almost 10 years.Citation33 The authors proposed the possibility that a sustained weight loss of more than that achieved in the intervention group may be required to reduce the risk of CVD. Furthermore, the mean loss of 3.5% of body weight in the control group is not typical of routine care, and may have contributed to the lower-than-expected CV event rate. The difference between groups may also have been reduced by an increased use of potentially cardioprotective drugs in the control group, as well as the provision of educational sessions. It may also be possible that any effect of lifestyle interventions on CV outcomes requires more than 10 years to become apparent, and would therefore not have been detected.Citation34 Nevertheless, several other benefits of intensive lifestyle intervention were reported, including reductions in urinary incontinence,Citation35 sleep apnea,Citation36 and depression,Citation37 and improvements in quality of life,Citation38 physical functioning,Citation39 and mobility.Citation40 Therefore, even though significant effects on CV morbidity and mortality were not demonstrated, this finding will not change the recommendation of weight loss for overweight and obese patients with T2DM.

Table 1 Trials and titles

On the topic of weight loss, it is also important to note that all the major diabetes guidelines refer to bariatric surgery.Citation25Citation27 The American Diabetes Association (ADA) guidelines state that bariatric surgery may be considered for adults with T2DM and a body mass index (BMI) >35 kg/m2, especially if the T2DM or associated comorbidities are difficult to control with lifestyle and pharmacological therapy.Citation25 Similarly, the American Association of Clinical Endocrinologists (AACE) guidelines state that bariatric surgery should be considered for patients with a BMI ≥35 kg/m2 and comorbidities, especially if therapeutic goals have not been reached using other strategies.Citation26 European diabetes guidelines mention that in obese individuals, bariatric surgery causes long-term weight loss and reduces the rate of incidence of T2DM and mortality.Citation27 Several studies have shown that bariatric surgery leads to near-normalization of hyperglycemia or remission of T2DM in 40%–95% of patients, although the mechanisms underlying these metabolic effects of bariatric surgery are unclear.Citation41Citation48 Some evidence also suggests that bariatric surgery is associated with reduced cardiovascular events and mortality. However, this is based on results from a nonrandomized study in which the control group was contemporaneously matched and differed by several characteristics at baseline.Citation49,Citation50 Therefore, the impact of bariatric surgery on cardiovascular risk is unclear, and appropriately controlled studies are required to clearly assess any impact.

Physical activity

Physical activity is recommended as part of weight-loss strategies, and the effects of weight loss on CVD risk were discussed in the previous section. However, physical activity is also thought to influence CVD risk independently of weight loss. The potential mechanisms underlying this link include decreased systemic inflammation, improved early diastolic filling, improved endothelial vasodilator function, and decreased abdominal visceral fat accumulation.Citation51 Most studies have shown a significant relative reduction in the incidence of CV events in participants who are physically active and/or aerobically fit, with a recent prospective meta-analysis of 12 cohort studies concluding that higher levels of total physical activity were associated with a lower CV mortality risk in individuals with diabetes.Citation52 Although there is considerable variation in the range of benefits reported, the recommendation to incorporate at least 150 minutes per week of moderate (to vigorous)Citation27 aerobic physical activity, in addition to resistance training at least twice a week, remains a cornerstone of T2DM management and prevention of CVD in T2DM.Citation25,Citation27

Smoking

A large body of evidence has established a causal link between cigarette smoking and health risks in the general population. In patients with T2DM, studies also consistently demonstrate that smoking is a risk factor for mortality and coronary heart disease, and to a lesser extent for stroke.Citation53Citation59 MRFIT (Multiple Risk Factor Intervention Trial) quantified an independent and increasing risk of coronary heart disease mortality based on the number of cigarettes smoked per day.Citation60 Although several studies have shown the benefits of quitting smoking in patients with diabetes, the potential consequence of weight gain may discourage patients from attempting to quit. A recent study investigating the link between smoking cessation and weight gain demonstrated CV benefits of smoking cessation in adults without diabetes, despite subsequent weight gain. The same trend was demonstrated for patients with diabetes, although it did not reach statistical significance, possibly because of limited study power.Citation61 Diabetes guidelines universally recommend that all patients should be advised not to smoke, and that smoking-cessation counseling and other forms of treatments should be included as routine components of diabetes care.Citation25,Citation27

Glucose control

In the context of elevated blood glucose, the function of the vascular endothelium is altered in ways that promote atherosclerosis (reviewed in Bornfeldt and TabasCitation62). While epidemiological and pathophysiological studies clearly support the hypothesis that hyperglycemia is associated with an increased risk of CVD, they do not directly address whether interventions to improve hyperglycemia reduce this risk.Citation63 Historically, one of the most contentious issues in the diabetes field is whether improved glycemic control is associated with a reduction in CVD, and following on from that, where glycated hemoglobin (HbA1c) targets should be set.

In type 1 diabetes mellitus, DCCT (Diabetes Control and Complications Trial) showed a trend towards a lower risk of CV events with intensive glucose control, but the number of events was small and the result was not statistically significant.Citation64 However, EDIC (Epidemiology of Diabetes Interventions and Complications), a 9-year follow-up of the DCCT cohort, showed that participants who were initially randomized to the intensive glucose-control arm had a 42% reduction of CV outcomes (95% confidence interval [CI] 9%–63%) and a 57% reduction in the risk of nonfatal myocardial infarction, stroke, or CV death (95% CI 12%–79%).Citation65 These findings demonstrate that an initial period of intensive glucose control had a sustained beneficial effect on CVD risk. The mechanisms underlying this legacy effect are not fully understood. A follow-up of the EDIC cohort 15 years after the study stopped found no significant difference between the intensive- and standard-care groups in terms of cardiac function or remodeling assessed by cardiac magnetic resonance imaging.Citation66

Such remarkable CV benefits have not been demonstrated in T2DM. On the one hand, in UKPDS (United Kingdom Prospective Diabetes Study), a study begun in the 1970s to compare intensive glucose control with the conventional treatment of the time in patients with newly diagnosed T2DM, there was evidence, albeit inconclusive, of a CV benefit of intensive glucose control, with a 16% reduction in the risk of myocardial infarction.Citation67 The aim of intensive treatment was fasting plasma glucose <6 mmol/L (108 mg/dL), making it difficult to compare this study with more recent investigations that used HbA1c targets. Nevertheless, a legacy effect, as seen in DCCT/EDIC, was demonstrated in the 10-year follow-up of UKPDS, with patients who were originally randomized to receive intensive glucose therapy achieving a significant reduction in the risk of myocardial infarction and all-cause mortality.Citation68

On the other hand, two large CV outcome trials, ADVANCE (Action in Diabetes and Vascular disease: PreterAx and Diamicron – MR Controlled Evaluation)Citation69 and VADT (Veterans Affairs and Diabetes Trial),Citation70 which prospectively examined the effects of intensive glucose control on macrovascular outcomes, showed no significant reduction in CVD risk with intensification of glucose control. A third trial, ACCORD (Action to Control Cardiovascular Risk in Diabetes),Citation71 was prematurely terminated, due to increased mortality in participants randomized to an intensive glucose-control strategy.

Although several meta-analyses have explored this controversial relationship between glucose control and CVD, these studies are not strictly comparable, making it impossible to draw firm conclusions. In summary, improved glucose control in patients with T2DM has not been definitively shown to reduce CVD, although a trend toward benefit has been observed. Based on ACCORD, ADVANCE, and VADT, Skyler et al suggest that glucose control plays a greater role before macrovascular disease is well developed and a minimal role when it is advanced, and that significant benefit is only seen in subsets of patients with shorter T2DM duration, lower baseline HbA1c, and/or absence of known CVD.Citation63 Furthermore, any benefit of glucose control on CVD risk in T2DM is likely to be modest compared with treatment of other CVD risk factors, and therefore difficult to demonstrate in their presence.Citation63 This resonates with the Look AHEAD weight-loss trial, where potential CV benefits in the intervention group may have been masked by efficient treatment of other risk factors in the control group, and highlights an ongoing difficulty with the design of CV outcome trials.

Current guidelines suggest a target HbA1c ≤6.5% (AACE) or <7.0% (ADA) for patients with short diabetes duration, long life expectancy, no significant CVD, and at low hypoglycemia risk.Citation25,Citation27 However, all guidelines emphasize the importance of individualization of targets, especially for patients with concurrent illness and at risk for hypoglycemia. The AACE guideline suggests a target HbA1c of >6.5% if lower targets cannot be achieved without adverse outcomes.Citation26 The ADA suggests a less stringent goal (than their general target of <7.0%) for patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, extensive comorbid conditions, and those with long-standing diabetes.Citation25 Furthermore, all guidelines recognize that any comprehensive diabetes-care plan should include modification of other CVD risk factors and also provide recommendations to this effect.

Although beneficial effects of glucose control on CVD risk have not been conclusively demonstrated, the benefits of good glucose control on microvascular outcomes are unequivocal, and antihyperglycemic agents therefore remain a cornerstone of T2DM treatment. There are many such agents to choose from and several factors for the physician to consider, including safety. The CV safety of certain antihyperglycemic drugs, particularly rosiglitazone and some sulfonylureas, has been called into question.Citation72,Citation73 This has led to much debate and controversy, although recent studies demonstrated that rosiglitazone did not increase the risk of CV overall morbidity and mortality any more than other standard glucose-lowering agents.Citation74,Citation75 Nevertheless, partly as a result of the rosiglitazone experience, the US Food and Drug Administration (FDA) recognized the need for safety data and issued guidance in 2008 making it essential for manufacturers to demonstrate that a new antidiabetes therapy is not associated with an unacceptable increase in CV risk.Citation76 As a result of this change in the regulatory landscape, several large CV-outcome trials are ongoing or have recently been completed ().

Table 2 Cardiovascular outcomes trials in diabetes

The FDA guidance applies to drugs approved since 2008, and thus many of these trials involve incretin-based therapies (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists) and sodium glucose cotransporter (SGLT)-2 inhibitors, as these are the most recently developed antihyperglycemic drug classes. There has been cautious optimism that incretin-based therapies may have CV benefits beyond those attributed to reducing hyperglycemia, with evidence of cardioprotective actions in preclinical models of CV dysfunction and beneficial effects on cardiac function in short-term clinical studies of ischemic heart disease.Citation77Citation79 However, this optimism has been tempered by results of SAVOR-TIMI (Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus – Thrombolysis in Myocardial Infarction) 53 and EXAMINE (EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome), which demonstrated the safety of saxagliptin and alogliptin, respectively, but failed to show a benefit on CV outcomes in either case.Citation80,Citation81 Therefore, while early studies for SGLT2 inhibitors also suggest they may have beneficial effects on CVD risk (in particular, as they are associated with lowering blood pressure and inducing weight loss),Citation82 the ongoing CV-outcome trials are essential to provide conclusive information on clinical outcomes (see ).

Blood pressure control

The pathophysiological relationship between hypertension and diabetes is complex and not well understood. Evidence suggests that insulin resistance plays a significant role in the interplay between diabetes, hypertension, and CVD, but such comorbidities as obesity and dyslipidemia make it difficult to decipher the common pathological mechanisms. Nevertheless, various studies indicate that the presence of hypertension is a very strong driver of CV outcomes in individuals with diabetes.Citation90,Citation91 Further evidence suggests that CVD risk starts to increase above a blood pressure of 115/75, and is then doubled for every 20 mmHg increase in systolic blood pressure, or for every 10 mmHg increase in diastolic blood pressure.Citation92 In contrast to hyperglycemia, several clinical investigations have shown that lowering blood pressure in patients with hypertension and diabetes reduces the risk of cerebrovascular accidents and congestive heart failure.Citation93Citation98 In spite of this evidence, hypertension is reportedly the most poorly controlled of the cardiac risk factors in this population.Citation15Citation17

Furthermore, the treatment of hypertension has also raised controversies in the context of choosing blood pressure targets, with some arguments for targets of 130/80 or even lower,Citation99,Citation100 and others for targets below 140/80 mmHg.Citation101Citation105 This controversy is reflected in the targets recommended by different clinical practice guidelines. Until recently, various guidelines and position statements were strikingly consistent in setting a target blood pressure level at 130/80 mmHg. However, recent guidelines on hypertension management for patients with diabetes issued by the ADA and European Society of Hypertension/European Society of Cardiology/European Association for the Study of Diabetes include a systolic blood pressure target of <140 mmHg.Citation25,Citation27 On the other hand, the AACE algorithm maintains its recommendation of a target in the region of 130/80 mmHg.Citation26 shows only major US and international guidelines issued in the last three years, as these were able to take into account the most recent investigations. Although there are discrepancies between the recommendations, what is clear is that patients with diabetes should be treated to a target blood pressure of at least <140/80 mmHg, but the physician will need to consider the individual’s overall health when setting any further targets.

Table 3 Recommended blood pressure targets

Intensive lifestyle intervention may be sufficient to lower blood pressure in patients with mild hypertension.Citation25Citation27 However, additional pharmacological intervention will be required for most patients. A wide variety of blood pressure-lowering agents, including angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin-receptor blockers (ARBs), β-blockers, diuretics, and calcium-channel blockers, have been shown to be effective in reducing the risk of CV events. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended a thiazide diuretic as the first line of treatment.Citation108 This guidance was based on the findings of ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), which showed that chlorthalidone was superior to other agents in preventing heart failure.Citation109 However, many other studies provide evidence that blockade of the renin–angiotensin–aldosterone system (RAAS) with an ACE-I or an ARB is particularly valuable for the treatment of hypertension in T2DM patients with high CVD risk.Citation110Citation118

The most up-to-date diabetes guidelines recommend an ACE-I or ARB as the first line of therapy.Citation25Citation27 Multiple drug therapy is generally required to achieve blood pressure targets, although ACE-I/ARB combinations are not recommended, as ONTARGET (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) showed they are associated with an increased risk of renal failure and hyperkalemia.Citation119 The AACE algorithm for CVD risk-factor modification recommends dual therapy with an RAAS blocker and a thiazide, calcium-channel blocker, or β-blocker when blood pressure is >150/100 mmHg, or when goals are not met.Citation26 RAAS blockade is usually the cornerstone of combination therapy, with a thiazide diuretic or a calcium-channel blocker often recommended as an add-on. ACCOMPLISH (Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension) compared these combinations, and showed superiority of an ACE-I/calcium-channel blocker combination over an ACE-I/thiazide diuretic combination.Citation120 In light of these findings, a combination of an RAAS blocker and a calcium-channel blocker is often proposed as a first choice.Citation121 However, this should not imply that other combinations are ineffective or harmful.Citation122 Indeed, there is such an array of antihypertensive options that the choice may be bewildering; however, a meta-analysis of 27 randomized trials concluded that all of the major classes of blood pressure-lowering agents are likely to substantially reduce CV risk.Citation123 This emphasizes the priority of blood pressure lowering per se, regardless of the choice of drug class. Nevertheless, individualization is always appropriate, eg, patients with heart failure could benefit from β-blockers, those with proteinuria from RAAS blockade, those with prostatism from α-blockers, and those with coronary artery disease from β-blockers or calcium-channel blockers.Citation26

Dyslipidemia

Dyslipidemia is strikingly common in patients with T2DM. The altered lipid profile associated with T2DM is most commonly attributed to insulin resistance,Citation124,Citation125 and is generally characterized by a high concentration of plasma triglycerides, low concentration of high-density lipoprotein cholesterol (HDL-C), and increased concentration of small dense LDL-C particles. A multivariate analysis from UKPDS found that an increased concentration of LDL-C was the strongest independent predictor of CVD, followed by decreased concentrations of HDL-C.Citation55 Indeed, several studies have shown that lowering LDL-C (usually with statins) reduces the risk of major CV events in patients with diabetes.Citation126Citation132 While HDL-C is a strong CVD risk predictor, numerous studies of pharmacological interventions to raise HDL-C have not found evidence of a beneficial effect on CV risk.Citation133Citation137 Similarly, although there is an association between elevated triglycerides and CVD, the degree to which triglycerides directly promote CVD has long been debated. Currently, very little clinical evidence exists to show that lowering triglycerides leads to a reduction of CVD risk,Citation138 although in the ACCORD lipid trial, a subgroup of patients who had the highest baseline triglyceride level and lowest HDL-C baseline level appeared to benefit from combination therapy with a statin plus a fibrate.Citation135

In 2004, the US National Cholesterol Education Panel Adult Panel III guidelines emphasized the importance of lowering elevated levels of LDL-C as the most effective treatment to reduce the incidence of coronary heart disease mortality and morbidity.Citation139 Management of LDL-C concentrations remains a major goal of diabetes treatment, with current guidelines emphasizing lowering LDL-C to a target goal of <100 mg/dL for T2DM patients without overt CVD.Citation25Citation27 Lifestyle interventions along with improved glycemic control may allow some patients to reach this lipid goal; however, pharmacological agents should be added if there is an inadequate response to lifestyle modifications, or in cases of high CVD risk. In patients with overt CVD or older than 40 years with other CVD risk factors, pharmacological treatment should be added to lifestyle therapy regardless of baseline lipid levels; an LDL-C target of <70 mg/dL is appropriate for such high-risk patients.Citation25Citation27 If statin-treated patients do not reach targets on maximum tolerated doses, the ADA guideline suggests a 30%–40% LDL-C reduction from baseline as an acceptable alternative target, while other guidelines recommend at least a ≥50% reduction if goals cannot be reached.Citation27 Statins are the drug of choice for lowering LDL-C; however, the ADA guideline also mentions additional LDL-C-lowering agents, including niacin, fenofibrate, ezetimibe, and bile-acid sequestrants, and these are included in the AACE CVD risk factor-modification algorithm as options to be used in combination with a statin to lower LDL-C.Citation26 However, without evidence that such combination therapy provides any significant improvement in CVD risk reduction, this approach is not broadly recommended by the ADA.

Although it is unclear whether modifying HDL-C and triglyceride levels impacts CVD risk, target goals for these parameters have nevertheless been incorporated into ADA and AACE guidelines, with both recommending lifestyle modifications and referring to the use of omega-3 fish oil, fibrates, and niacin to achieve target triglyceride levels <150 mg/dL.Citation25,Citation26 The ADA guideline states that HDL-C targets of >40 mg/dL in men and >50 mg/dL in women are desirable, and mentions the use of niacin and fibrates to increase HDL-C levels, even though their effect on CVD outcomes in patients with diabetes is unclear. The AACE CVD risk factor-modification algorithm proposes a non-HDL-C (total cholesterol minus HDL-C) level of <130 mg/dL, and also identifies fibrates, niacin, and omega-3 fish oil as treatment options.

Although it is encouraging to note that the proportion of patients meeting LDL-C goals has improved over time, recent analyses indicate that LDL-C levels remain uncontrolled in over 45% of patients with T2DM.Citation140,Citation141 Intensification of efforts to achieve lipid goals in clinical practices therefore provides an opportunity to have an impact on overall CV risk in patients with diabetes.

Antiplatelet therapy

Prothrombotic and fibrinolytic mechanisms are tightly regulated under normal circumstances, such that there is protection from bleeding without the formation of pathological thrombosis. However, in patients with diabetes, this regulation is disrupted, and there is an increased thrombotic tendency, due to platelet hyperreactivity, decreased fibrinolysis, and increased activation of prothrombotic coagulation factors (eg, tissue factor, factor VIII, thrombin, fibrinogen, plasminogen-activator inhibitor 1).Citation142,Citation143 A number of antiplatelet agents have been shown to be of benefit for the prevention of CV events in certain groups, with aspirin being the most commonly used. Aspirin inhibits thromboxane A2-dependent platelet activation and aggregation by way of its irreversible inhibition of cyclooxygenase 1, and a number of studies have demonstrated that treatment with low-dose aspirin resulted in a significant reduction of serious vascular events in patients with diabetes and CVD.Citation144Citation146

The evidence regarding the use of aspirin for primary prevention of CV events in adults with diabetes is more controversial. For example, two recent randomized controlled trials did not show a significant CV benefit of aspirin in patients with diabetes.Citation147,Citation148 These trials were included in a recent meta-analysis that also incorporated data from seven other trials, either performed specifically in patients with diabetes, or that included subgroups of patients with diabetes.Citation149 Across trials, aspirin was associated with a 9% decrease in risk of coronary events and a 10% reduction in the risk of stroke; however, the decrease in risk for both outcomes did not reach statistical significance. These results are consistent with the findings of other meta-analyses,Citation150Citation154 and together they suggest that aspirin may produce a modest reduction in the risk of CV events in patients with diabetes. However, aspirin use is also associated with a significant increase in the risk of intracranial and extracranial hemorrhage, and the relative trade-off between CV events prevented by aspirin and bleeding events caused by aspirin therefore needs careful consideration.Citation149 Further studies are required to assess more reliably the benefit-to-risk ratio of aspirin in primary prevention in T2DM patients at moderate CV risk. To address this, ACCEPT-D (Aspirin and simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes)Citation155 and ASCEND (A Study of Cardiovascular Events iN Diabetes) are two large ongoing trials that collectively will include more than 15,000 participants with diabetes. These investigations will provide important information about the role of aspirin for primary prevention in patients with diabetes, and may help identify which patients are at greatest risk, and therefore which patients stand to derive a net benefit from aspirin therapy.

Platelet P2Y12-receptor blockers are an alternative class of antiplatelet agents that include clopidogrel, prasugrel, and ticagrelor. Clopidogrel inhibits adenosine diphosphate-dependent platelet function by irreversible inhibition of the platelet P2Y12 receptor, and has proven clinical efficacy in reducing CV events in patients with diabetes.Citation156 However, its inhibition is less predictable than the inhibition of thromboxane A2-dependent platelet activation by aspirin, and genetic variation of relevant liver enzymes, as well as drug–drug interactions with proton-pump inhibitors, can affect clopidogrel’s mechanism of action, leading to a variable clinical response to treatment.Citation157 Furthermore, various studies suggest a clinically relevant suboptimal clopidogrel response in at least some patients with diabetes.Citation158

Prasugrel also exerts its antiplatelet effect by irreversible inhibition of the P2Y12 receptor; however, it leads to platelet inhibition more rapidly and with less variability compared with clopidogrel. It is currently indicated for the reduction of thrombotic CV events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention. TRITON-TIMI (TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel – Thrombolysis In Myocardial Infarction) 38 demonstrated that prasugrel produced a greater reduction in ischemic events than clopidogrel, but was associated with an increased risk of bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Citation159 Interestingly, a subgroup of patients with T2DM derived the highest benefit from prasugrel without an increased risk of major bleeding.Citation160 On the other hand, another study that compared prasugrel with clopidogrel in the context of acute coronary syndromes without revascularization did not demonstrate an increased benefit of prasugrel for reducing ischemic events in the general cohort or in a diabetes subgroup; furthermore, similar risks of bleeding were observed with both antiplatelet agents.Citation161

Ticagrelor also inhibits P2Y12 receptors, but differs from clopidogrel and prasugrel by virtue of its direct and reversible mechanism of action. PLATO (Platelet Inhibition And Patient Outcomes) demonstrated that ticagrelor was more effective than clopidogrel in reducing death from CV causes and total mortality in a general postacute coronary syndrome cohort,Citation162 and decreased ischemic events in diabetes patients without increasing the risk of bleeding.Citation163 In a recent small study (30 patients) that compared ticagrelor and prasugrel in acute coronary syndrome patients with diabetes, ticagrelor achieved a significantly higher platelet inhibition than prasugrel;Citation164 however, no clinical relevance of these findings has so far been demonstrated.

Current guidelines recommend aspirin therapy as a potential primary prevention strategy in those with diabetes who are at increased CVD risk and who are not at increased risk for bleeding.Citation25,Citation27 However, a net benefit of aspirin use for the primary prevention of CVD has not been unequivocally demonstrated, and thus aspirin is no longer recommended for those with diabetes at low CVD risk.Citation25,Citation27,Citation149 Low-dose aspirin therapy (75–162 mg/day) is recommended as a secondary prevention strategy in those with diabetes with a history of CVD, and clopidogrel as an alternative therapy in aspirin-intolerant patients.Citation25,Citation27 Use of a P2Y12-receptor antagonist in combination with aspirin for at least 1 year in patients following acute coronary syndrome is recommended by the ADA. The ADA guideline also draws attention to the fact that evidence supports the use of either ticagrelor or clopidogrel if no percutaneous coronary intervention was performed, and the use of clopidogrel, ticagrelor, or prasugrel if percutaneous coronary intervention was performed.Citation25 The prescribing information for both ticagrelor and prasugrel contains a boxed warning regarding bleeding risk,Citation165,Citation166 and caution is therefore urged in patients with a high risk for bleeding.

Multifactorial approaches

Evidence suggests that targeted multifactorial intervention is of benefit for reducing CVD in the context of T2DM. In Steno-2 (Intensified Multifactorial Intervention in Patients with Type 2 Diabetes and Microalbuminuria), patients with T2DM and persistent microalbuminuria were randomized to receive either conventional intervention involving multiple risk factors, or intensified, targeted, multifactorial intervention involving a combination of medications and focused behavior modification.Citation167 Targets for HbA1c, systolic and diastolic blood pressure, and fasting values of serum total cholesterol, LDL-C, and triglycerides were lower in the intensified-intervention group than with conventional intervention. Although only 15% of patients in the intensive arm reached the HbA1c target of <6.5%, the risk of vascular complications was approximately halved in this group after a mean follow-up of 7.8 years. Few patients achieved all treatment goals (approximately 70% reached the total cholesterol target of <175 mg/dL, approximately 58% reached the triglyceride target of <150 mg/dL, almost 50% reached the systolic blood pressure goal of <130 mmHg, and approximately 70% reached the diastolic blood pressure goal of <80 mmHg).Citation167 Nevertheless, for most patients, the treatment goals for lipids and blood pressure were achievable without undue difficulties.Citation168

At the end of this study, all patients in both groups were informed in detail about the benefits of intensified multifactorial treatments, and the primary care providers to whom the patients were referred were educated about this approach. Patients were subsequently followed observationally for a mean of 5.5 years. This follow-up analysis demonstrated that the intensified multifactorial approach had sustained beneficial effects with respect to vascular complications: absolute mortality was reduced by 20%, and CV mortality was reduced by 13% in patients originally assigned to the intensively managed group, compared with those who received conventional therapy.Citation169 A recent study aiming to address the feasibility of a multifactorial intensive intervention in patients with T2DM of at least 2 years’ duration and no previous CV events demonstrated that such an approach is feasible and effective in clinical practice, and is associated with significant and durable improvements in CVD risk profile.Citation170

Conclusion

Early intervention has the greatest impact on micro- and macrovascular complications of T2DM. Glycemic control therapies should be started as soon as diabetes is detected, and early intervention for blood pressure and lipids is vital. Treatment strategies for these patients will evolve as new drugs are continually being developed. However, lifestyle changes are also essential to any management plan, and although many patients may need pharmacological therapy to reach targets, the benefits of a healthy lifestyle should not be underestimated. For a newly diagnosed patient, the range of risk factors requiring consideration may seem overwhelming. Integrated care teams incorporating diabetes educators can greatly help in this respect, providing the support patients need to make lifestyle changes, as well as adhere closely to treatment regimens. Working with the patient to target multiple risk factors with both lifestyle and pharmacological strategies needs time and effort, but gives the best chance of reducing the likelihood of microvascular and macrovascular complications in the long term.

Acknowledgments

Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Ann Kerrigan of Envision Scientific Solutions during the preparation of this review. Boehringer Ingelheim was given the opportunity to check the data used in the manuscript for factual accuracy only. The author was fully responsible for all content and editorial decisions, was involved at all stages of manuscript development, and has approved the final version of the review, which reflects the author’s interpretation and conclusions.

Disclosure

Dr Lorber is a board member of Biodel; has served as a consultant for Merck, Novo Nordisk, and Janssen; has received grants from MannKind, Eli Lilly, and Boehringer Ingelheim; has received payments for lectures from Novo Nordisk and Janssen; and owns stock in Biodel.

References

  • Cheng YJ Imperatore G Geiss LS Secular changes in the age-specific prevalence of diabetes among US adults: 1988–2010 Diabetes Care 2013 36 9 2690 2696 23637354
  • International Diabetes Federation IDF Diabetes Atlas 6th ed Brussels IDF 2013
  • Centers for Disease Control and Prevention National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States Atlanta CDC 2011
  • Barrett-Connor EL Cohn BA Wingard DL Edelstein SL Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study JAMA 1991 265 5 627 631 1987413
  • Fuller JH Shipley MJ Rose G Jarrett RJ Keen H Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study Br Med J (Clin Res Ed) 1983 287 6396 867 870
  • Kannel WB McGee DL Diabetes and cardiovascular disease. The Framingham study JAMA 1979 241 19 2035 2038 430798
  • Manson JE Colditz GA Stampfer MJ A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women Arch Intern Med 1991 151 6 1141 1147 2043016
  • Stamler J Vaccaro O Neaton JD Wentworth D Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 1993 16 2 434 444 8432214
  • Haffner SM Lehto S Rönnemaa T Pyörälä K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998 339 4 229 234 9673301
  • Franco OH Steyerberg EW Hu FB Mackenbach J Nusselder W Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease Arch Intern Med 2007 167 11 1145 1151 17563022
  • Behar S Boyko V Reicher-Reiss H Goldbourt U Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial Am Heart J 1997 133 3 290 296 9060796
  • Mak KH Moliterno DJ Granger CB Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries J Am Coll Cardiol 1997 30 1 171 179 9207639
  • Malmberg K Yusuf S Gerstein HC Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry Circulation 2000 102 9 1014 1019 10961966
  • Gregg EW Cheng YJ Saydah S Trends in death rates among US adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey Diabetes Care 2012 35 6 1252 1257 22619288
  • Farkouh ME Boden WE Bittner V Risk factor control for coronary artery disease secondary prevention in large randomized trials J Am Coll Cardiol 2013 61 15 1607 1615 23500281
  • Joseph J Svartberg J Njølstad I Schirmer H Change in cardiovascular risk factors in relation to diabetes status: the Tromso Study Eur J Prev Cardiol 2012 19 3 551 557 21505026
  • Saydah SH Fradkin J Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes JAMA 2004 291 3 335 342 14734596
  • Haffner SM Pre-diabetes, insulin resistance, inflammation and CVD risk Diabetes Res Clin Pract 2003 61 Suppl 1 S9 S18 12880690
  • Preis SR Pencina MJ Hwang SJ Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study Circulation 2009 120 3 212 220 19581493
  • Helfand M Buckley DI Freeman M Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the US. Preventive Services Task Force Ann Intern Med 2009 151 7 496 507 19805772
  • US Preventive Services Task Force Using nontraditional risk factors in coronary heart disease risk assessment: US Preventive Services Task Force recommendation statement Ann Intern Med 2009 151 7 474 482 19805770
  • Fonseca V Desouza C Asnani S Jialal I Nontraditional risk factors for cardiovascular disease in diabetes Endocr Rev 2004 25 1 153 175 14769830
  • Resnick HE Howard BV Diabetes and cardiovascular disease Annu Rev Med 2002 53 245 267 11818473
  • Muntner P He J Chen J Fonseca V Whelton PK Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III) Ann Epidemiol 2004 14 9 686 695 15380800
  • American Diabetes Association Standards of medical care in diabetes 2014 Diabetes Care 2014 37 Suppl 1 S14 S80 24357209
  • Garber AJ Abrahamson MJ Barzilay JI American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement – executive summary Endocr Pract 2013 19 3 536 557 23816937
  • Rydén L Grant PJ Anker SD ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) Eur Heart J 2013 34 39 3035 3087 23996285
  • Bogers RP Bemelmans WJ Hoogenveen RT Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons Arch Intern Med 2007 167 16 1720 1728 17846390
  • Chan JM Rimm EB Colditz GA Stampfer MJ Willett WC Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men Diabetes Care 1994 17 9 961 969 7988316
  • Colditz GA Willett WC Rotnitzky A Manson JE Weight gain as a risk factor for clinical diabetes mellitus in women Ann Intern Med 1995 122 7 481 486 7872581
  • Shoelson SE Lee J Goldfine AB Inflammation and insulin resistance J Clin Invest 2006 116 7 1793 1801 16823477
  • Donath MY Shoelson SE Type 2 diabetes as an inflammatory disease Nat Rev Immunol 2011 11 2 98 107 21233852
  • Wing RR Bolin P Brancati FL Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes N Engl J Med 2013 369 2 145 154 23796131
  • Gerstein HC Do lifestyle changes reduce serious outcomes in diabetes? N Engl J Med 2013 369 2 189 190 23796132
  • Phelan S Kanaya AM Subak LL Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial J Urol 2012 187 3 939 944 22264468
  • Foster GD Borradaile KE Sanders MH A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study Arch Intern Med 2009 169 17 1619 1626 19786682
  • Faulconbridge LF Wadden TA Rubin RR One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study Obesity (Silver Spring) 2012 20 4 783 793 22016099
  • Williamson DA Rejeski J Lang W Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes Arch Intern Med 2009 169 2 163 171 19171813
  • Foy CG Lewis CE Hairston KG Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial Obesity (Silver Spring) 2011 19 1 83 93 20559303
  • Rejeski WJ Ip EH Bertoni AG Lifestyle change and mobility in obese adults with type 2 diabetes N Engl J Med 2012 366 13 1209 1217 22455415
  • Ikramuddin S Korner J Lee WJ Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial JAMA 2013 309 21 2240 2249 23736733
  • Schauer PR Kashyap SR Wolski K Bariatric surgery versus intensive medical therapy in obese patients with diabetes N Engl J Med 2012 366 17 1567 1576 22449319
  • Mingrone G Panunzi S De Gaetano A Bariatric surgery versus conventional medical therapy for type 2 diabetes N Engl J Med 2012 366 17 1577 1585 22449317
  • Dorman RB Serrot FJ Miller CJ Case-matched outcomes in bariatric surgery for treatment of type 2 diabetes in the morbidly obese patient Ann Surg 2012 255 2 287 293 21975321
  • Buchwald H Estok R Fahrbach K Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis Am J Med 2009 122 3 248 256.e245 19272486
  • Dixon JB O’Brien PE Playfair J Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial JAMA 2008 299 3 316 323 18212316
  • Cohen RV Pinheiro JC Schiavon CA Salles JE Wajchenberg BL Cummings DE Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity Diabetes Care 2012 35 7 1420 1428 22723580
  • Mingrone G Castagneto-Gissey L Type 2 diabetes mellitus in 2013: a central role of the gut in glucose homeostasis Nat Rev Endocrinol 2014 10 2 73 74 24322651
  • Sjöström L Peltonen M Jacobson P Bariatric surgery and long-term cardiovascular events JAMA 2012 307 1 56 65 22215166
  • Sjöström L Narbro K Sjöström CD Effects of bariatric surgery on mortality in Swedish obese subjects N Engl J Med 2007 357 8 741 752 17715408
  • Stewart KJ Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health JAMA 2002 288 13 1622 1631 12350193
  • Sluik D Buijsse B Muckelbauer R Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis Arch Intern Med 2012 172 17 1285 1295 22868663
  • Ford ES DeStefano F Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study Am J Epidemiol 1991 133 12 1220 1230 2063830
  • Morrish NJ Stevens LK Fuller JH Jarrett RJ Keen H Risk factors for macrovascular disease in diabetes mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease in Diabetics Diabetologia 1991 34 8 590 594 1936663
  • Turner RC Millns H Neil HA Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 1998 316 7134 823 828 9549452
  • Al-Delaimy WK Manson JE Solomon CG Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus Arch Intern Med 2002 162 3 273 279 11822919
  • Al-Delaimy WK Willett WC Manson JE Speizer FE Hu FB Smoking and mortality among women with type 2 diabetes: the Nurses’ Health Study cohort Diabetes Care 2001 24 12 2043 2048 11723080
  • Qin R Chen T Lou Q Yu D Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies Int J Cardiol 2013 167 2 342 350 22251416
  • Nilsson PM Cederholm J Eeg-Olofsson K Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register Eur J Cardiovasc Prev Rehabil 2009 16 4 506 512 19561510
  • Neaton JD Wentworth D Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group Arch Intern Med 1992 152 1 56 64 1728930
  • Clair C Rigotti NA Porneala B Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes JAMA 2013 309 10 1014 1021 23483176
  • Bornfeldt KE Tabas I Insulin resistance, hyperglycemia, and atherosclerosis Cell Metab 2011 14 5 575 585 22055501
  • Skyler JS Bergenstal R Bonow RO Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Circulation 2009 119 2 351 357 19095622
  • Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 14 977 986 8366922
  • Nathan DM Cleary PA Backlund JY Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 2005 353 25 2643 2653 16371630
  • Genuth SM Backlund JY Bayless M Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC Diabetes 2013 62 10 3561 3569 23520132
  • UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 9131 837 853 9742976
  • Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-Year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
  • Patel A MacMahon S Chalmers J Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 24 2560 2572 18539916
  • Duckworth W Abraira C Moritz T Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 2 129 139 19092145
  • Gerstein HC Miller ME Byington RP Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 24 2545 2559 18539917
  • Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007 356 24 2457 2471 17517853
  • Riddle MC More reasons to say goodbye to glyburide J Clin Endocrinol Metab 2010 95 11 4867 4870 21051583
  • Home PD Pocock SJ Beck-Nielsen H Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 2009 373 9681 2125 2135 19501900
  • Mahaffey KW Hafley G Dickerson S Results of a reevaluation of cardiovascular outcomes in the RECORD trial Am Heart J 2013 166 2 240 249.e1 23895806
  • US Food and Drug Administration Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Accessed January 8, 2014
  • Ussher JR Drucker DJ Cardiovascular biology of the incretin system Endocr Rev 2012 33 2 187 215 22323472
  • Green JB The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety Postgrad Med 2012 124 4 54 61 22913894
  • Lorber D GLP-1 receptor agonists: effects on cardiovascular risk reduction Cardiovasc Ther 2013 31 4 238 249 23865382
  • White WB Cannon CP Heller SR Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 2013 369 14 1327 1335 23992602
  • Scirica BM Bhatt DL Braunwald E Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 369 14 1317 1326 23992601
  • Riser Taylor S Harris KB The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus Pharmacotherapy 2013 33 9 984 999 23744749
  • Neal B Perkovic V de Zeeuw D Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial Am Heart J 2013 166 2 217 223.e11 23895803
  • Rosenstock J Marx N Kahn SE Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial Diab Vasc Dis Res 2013 10 4 289 301 23449634
  • Marso SP Poulter NR Nissen SE Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial Am Heart J 2013 166 5 823 830.e5 24176437
  • Vaccaro O Masulli M Bonora E The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes Diabetes Care 2012 35 12 e82 23173143
  • Punthakee Z Bosch J Dagenais G Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial Diabetologia 2012 55 1 36 45 22038523
  • Lincoff AM Tardif JC Neal B Evaluation of the dual peroxisome proliferator-activated receptor alpha/gamma agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial Am Heart J 2013 166 3 429 434 24016490
  • ORIGIN Trial Investigators Gerstein HC Bosch J Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 2012 367 4 319 328 22686416
  • Chen G McAlister FA Walker RL Hemmelgarn BR Campbell NR Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure Hypertension 2011 57 5 891 897 21403089
  • Sarwar N Gao P Seshasai SR Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 2010 375 9733 2215 2222 20609967
  • Lewington S Clarke R Qizilbash N Peto R Collins R Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 2002 360 9349 1903 1913 12493255
  • Curb JD Pressel SL Cutler JA Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group JAMA 1996 276 23 1886 1892 8968014
  • Tuomilehto J Rastenyte D Birkenhäger WH Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators N Engl J Med 1999 340 9 677 684 10053176
  • Patel A MacMahon S Chalmers J Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 2007 370 9590 829 840 17765963
  • Hansson L Zanchetti A Carruthers SG Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 1998 351 9118 1755 1762 9635947
  • UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group BMJ 1998 317 7160 703 713 9732337
  • Schrier RW Estacio RO Esler A Mehler P Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 2002 61 3 1086 1097 11849464
  • Rutter MK Nesto RW Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care Eur Heart J 2011 32 18 2247 2255 21705358
  • Reboldi G Gentile G Angeli F Ambrosio G Mancia G Verdecchia P Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients J Hypertens 2011 29 7 1253 1269 21505352
  • Arguedas JA Perez MI Wright JM Treatment blood pressure targets for hypertension Cochrane Database Syst Rev 2009 3 CD004349 19588353
  • Cooper-DeHoff RM Gong Y Handberg EM Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease JAMA 2010 304 1 61 68 20606150
  • Bangalore S Kumar S Lobach I Messerli FH Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials Circulation 2011 123 24 2799 2810 21632497
  • Sleight P Redon J Verdecchia P Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study J Hypertens 2009 27 7 1360 1369 19506526
  • Redon J Mancia G Sleight P Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) J Am Coll Cardiol 2012 59 1 74 83 22192672
  • Mancia G Fagard R Narkiewicz K 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 2013 31 7 1281 1357 23817082
  • International Diabetes Federation Global Guideline for Type 2 Diabetes Brussels IDF 2012
  • Chobanian AV Bakris GL Black HR Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 2003 42 6 1206 1252 14656957
  • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 2002 288 23 2981 2997 12479763
  • Tatti P Pahor M Byington RP Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM Diabetes Care 1998 21 4 597 603 9571349
  • Estacio RO Jeffers BW Hiatt WR Biggerstaff SL Gifford N Schrier RW The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension N Engl J Med 1998 338 10 645 652 9486993
  • Lindholm LH Hansson L Ekbom T Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group J Hypertens 2000 18 11 1671 1675 11081782
  • Niskanen L Hedner T Hansson L Lanke J Niklason A Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project Diabetes Care 2001 24 12 2091 2096 11723089
  • Lindholm LH Ibsen H Dahlöf B Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 2002 359 9311 1004 1010 11937179
  • McMurray JJ Ostergren J Swedberg K Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 2003 362 9386 767 771 13678869
  • Pfeffer MA Swedberg K Granger CB Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 2003 362 9386 759 766 13678868
  • Granger CB McMurray JJ Yusuf S Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 2003 362 9386 772 776 13678870
  • Schrier RW Estacio RO Mehler PS Hiatt WR Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial Nat Clin Pract Nephrol 2007 3 8 428 438 17653121
  • ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 2008 358 15 1547 1559 18378520
  • Jamerson K Weber MA Bakris GL Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 2008 359 23 2417 2428 19052124
  • Aksnes TA Skårn SN Kjeldsen SE Treatment of hypertension in diabetes: what is the best therapeutic option? Expert Rev Cardiovasc Ther 2012 10 6 727 734 22894629
  • Reboldi G Gentile G Angeli F Verdecchia P Optimal therapy in hypertensive subjects with diabetes mellitus Curr Atheroscler Rep 2011 13 2 176 185 21234720
  • Turnbull F Neal B Algert C Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials Arch Intern Med 2005 165 12 1410 1419 15983291
  • Krentz AJ Lipoprotein abnormalities and their consequences for patients with type 2 diabetes Diabetes Obes Metab 2003 5 Suppl 1 S19 S27 14984018
  • Mooradian AD Dyslipidemia in type 2 diabetes mellitus Nat Clin Pract Endocrinol Metab 2009 5 3 150 159 19229235
  • Colhoun HM Betteridge DJ Durrington PN Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 2004 364 9435 685 696 15325833
  • Collins R Armitage J Parish S Sleigh P Peto R MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 2003 361 9374 2005 2016 12814710
  • Goldberg RB Mellies MJ Sacks FM Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators Circulation 1998 98 23 2513 2519 9843456
  • Kearney PM Blackwell L Collins R Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 2008 371 9607 117 125 18191683
  • Pyorala K Pedersen TR Kjekshus J Faergeman O Olsson AG Thorgeirsson G Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 1997 20 4 614 620 9096989
  • Sever PS Poulter NR Dahlöf B Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA) Diabetes Care 2005 28 5 1151 1157 15855581
  • Shepherd J Barter P Carmena R Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study Diabetes Care 2006 29 6 1220 1226 16731999
  • Briel M Ferreira-Gonzalez I You JJ Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ 2009 338 b92 19221140
  • Singh IM Shishehbor MH Ansell BJ High-density lipoprotein as a therapeutic target: a systematic review JAMA 2007 298 7 786 798 17699012
  • ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 2010 362 17 1563 1574 20228404
  • Aim-High Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 2011 365 24 2255 2267 22085343
  • Schwartz GG Olsson AG Abt M Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 2012 367 22 2089 2099 23126252
  • Miller M Stone NJ Ballantyne C Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 2011 123 20 2292 2333 21502576
  • Grundy SM Cleeman JI Merz CN Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 2004 110 2 227 239 15249516
  • Wong ND Patao C Wong K Malik S Franklin SS Iloeje U Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status Diab Vasc Dis Res 2013 10 6 505 513 23975724
  • Ford ES Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: findings from the National Health and Nutrition Examination Survey 1999–2008 J Diabetes 2011 3 4 337 347 21767347
  • Alzahrani SH Ajjan RA Coagulation and fibrinolysis in diabetes Diab Vasc Dis Res 2010 7 4 260 273 20847109
  • Ferreiro JL Gómez-Hospital JA Angiolillo DJ Platelet abnormalities in diabetes mellitus Diab Vasc Dis Res 2010 7 4 251 259 20921090
  • Antiplatelet Trialists’ Collaboration Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 1994 308 6921 81 106 8298418
  • Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 2002 324 7329 71 86 11786451
  • ETDRS Investigators Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14 JAMA 1992 268 10 1292 1300 1507375
  • Belch J MacCuish A Campbell I The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 2008 337 a1840 18927173
  • Ogawa H Nakayama M Morimoto T Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 2008 300 18 2134 2141 18997198
  • Pignone M Alberts MJ Colwell JA Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation Diabetes Care 2010 33 6 1395 1402 20508233
  • Baigent C Blackwell L Collins R Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 2009 373 9678 1849 1860 19482214
  • De Berardis G Sacco M Strippoli GF Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials BMJ 2009 339 b4531 19897665
  • Zhang C Sun A Zhang P Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis Diabetes Res Clin Pract 2010 87 2 211 218 19853947
  • Calvin AD Aggarwal NR Murad MH Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes Diabetes Care 2009 32 12 2300 2306 19741185
  • Butalia S Leung AA Ghali WA Rabi DM Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis Cardiovasc Diabetol 2011 10 25 21453547
  • De Berardis G Sacco M Evangelista V Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins Trials 2007 8 21 17725825
  • Bhatt DL Marso SP Hirsch AT Ringleb PA Hacke W Topol EJ Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 2002 90 6 625 628 12231089
  • Patrono C Andreotti F Arnesen H Antiplatelet agents for the treatment and prevention of atherothrombosis Eur Heart J 2011 32 23 2922 2932 22019823
  • Hall HM Banerjee S McGuire DK Variability of clopidogrel response in patients with type 2 diabetes mellitus Diab Vasc Dis Res 2011 8 4 245 253 21933840
  • Wiviott SD Braunwald E McCabe CH Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 2007 357 20 2001 2015 17982182
  • Wiviott SD Braunwald E Angiolillo DJ Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – Thrombolysis in Myocardial Infarction 38 Circulation 2008 118 16 1626 1636 18757948
  • Roe MT Armstrong PW Fox KA Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 2012 367 14 1297 1309 22920930
  • Wallentin L Becker RC Budaj A Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 2009 361 11 1045 1057 19717846
  • James S Angiolillo DJ Cornel JH Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial Eur Heart J 2010 31 24 3006 3016 20802246
  • Alexopoulos D Xanthopoulou I Mavronasiou E Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes Diabetes Care 2013 36 8 2211 2216 23491524
  • Sankyo Daiichi Lilly Eli Effient (prasugrel) tablets [package insert] 2009 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022307s002lbl.pdf Accessed January 8, 2014
  • AstraZeneca Brilinta®(ticagrelor) tablets [package insert] 2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022433s008lbl.pdf Accessed January 8, 2014
  • Gaede P Vedel P Larsen N Jensen GV Parving HH Pedersen O Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 2003 348 5 383 393 12556541
  • Gaede P Pedersen O Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis Diabetes 2004 53 Suppl 3 S39 S47 15561920
  • Gaede P Lund-Andersen H Parving HH Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 2008 358 6 580 591 18256393
  • Vaccaro O Franzini L Miccoli R Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trial Diabetes Care 2013 36 9 2566 2572 23863908